Literature DB >> 6196396

Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.

J Y Niederkorn, J W Streilein.   

Abstract

Intracameral inoculation of allogeneic B16F10 melanoma cells (C57BL/6) into LP/J mice resulted in progressively growing intraocular tumors and impaired delayed-type hypersensitivity (DTH) reactivity. Additional experiments showed that DTH responses were specifically down-regulated by splenic T suppressor cells. By contrast, subcutaneous inoculation of B16F10 melanoma cells induced significant DTH responses to the alloantigens expressed on the tumor cells and stimulated brisk rejection of the subcutaneously injected tumor cells. In spite of the T suppressor cell inhibition of DTH reactivity, significant cytotoxic T lymphocyte activity could be demonstrated in lymphoid cell suspensions from hosts harboring allogeneic intraocular tumors. The demonstrated cytotoxic T lymphocyte activity is particularly noteworthy because it occurs in the face of severely suppressed DTH responsiveness and thus implies that the intracameral presentation of alloantigens evokes a precise immunoregulatory process that selectively and concomitantly modulates specific cellular immune components; one immune process (cytotoxic T lymphocyte function) is stimulated whereas the other (DTH responsiveness) is down-regulated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6196396

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  CTL induction of tumoricidal nitric oxide production by intratumoral macrophages is critical for tumor elimination.

Authors:  Rodolfo D Vicetti Miguel; Thomas L Cherpes; Leah J Watson; Kyle C McKenna
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

3.  CD55 Is Essential for CD103+ Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity.

Authors:  Michael G Strainic; Jinbo Liu; Fengqi An; Erin Bailey; Andrew Esposito; Jörg Hamann; Peter S Heeger; M Edward Medof
Journal:  Am J Pathol       Date:  2019-05-17       Impact factor: 4.307

Review 4.  Cell death and the immune response: a lesson from the privileged.

Authors:  T A Ferguson; T S Griffith
Journal:  J Clin Immunol       Date:  1997-01       Impact factor: 8.317

5.  Immune response to intraocular injection of retinal S-antigen in adjuvant.

Authors:  F G Roberge; Y de Kozak; T Utsumi; J P Faure; R B Nussenblatt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

6.  OVA-specific CD8+ T cells do not express granzyme B during anterior chamber associated immune deviation.

Authors:  Yalin Ren; Peizeng Yang; Bing Li; Yang Gao; Hongyan Zhou; Xiangkun Huang; Lianxiang Zhu; Aize Kijlstra
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

7.  In situ suppression of delayed-type hypersensitivity: another mechanism for sustaining the immune privilege of the anterior chamber.

Authors:  J L Benson; J Y Niederkorn
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

8.  Incomplete activation of lymphokine-producing T cells by alloantigenic intraocular tumours in anterior chamber-associated immune deviation.

Authors:  Y Bando; B R Ksander; J W Streilein
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

9.  Differential immune responses to fetal intracameral spinal cord and cortex cerebri grafts.

Authors:  M Shinoda; M Giacobini; R Schmidt-Kastner; K Trok; L Olson
Journal:  Exp Brain Res       Date:  1996-07       Impact factor: 1.972

10.  The role of ACAID and CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens.

Authors:  Daniel R Saban; Janet Cornelius; Sharmila Masli; Johannes Schwartzkopff; Maire Doyle; Sunil K Chauhan; Ammon B Peck; Maria B Grant
Journal:  Mol Vis       Date:  2008-12-19       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.